Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications.
about
New treatment options for late Na current, arrhythmias, and diastolic dysfunctionThe immediate future for the medical treatment of atrial fibrillationConstitutively Active Acetylcholine-Dependent Potassium Current Increases Atrial Defibrillation Threshold by Favoring Post-Shock Re-Initiation.Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control?Atrial tachyarrhythmia in adult congenital heart diseaseImportance of QT interval determination and renal function assessment during antiarrhythmic drug therapy.Drug-induced torsades de pointes and implications for drug development.Rhythm or rate control in atrial fibrillation: insights from the randomized controlled trials.Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters.Prevalence, prognostic significance, and treatment of atrial fibrillation in congestive heart failure with particular reference to the DIAMOND-CHF study.Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations.Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.Refractory atrial fibrillation effectively treated with ranolazine.Amiodarone-Induced Third Degree Atrioventricular Block and Extreme QT Prolongation Generating Torsade Des Pointes in Paroxysmal Atrial Fibrillation.Atrial-specific pathways for control of intracellular signaling and myocyte function.Antiarrhythmic and Arrhythmogenic Actions of Varying Levels of Extracellular Magnesium: Possible Cellular Basis for the Differences in the Efficacy of magnesium and Lidocaine in Torsade de Pointes.Restoring Sinus Rhythm in Patients With Atrial Flutter and Fibrillation: Pharmacologic or Electrical Cardioversion?Suppression of frequent ventricular ectopy in a patient with hypertrophic heart disease with ranolazine: a case report.Pharmacodynamic effect of continuous vs intermittent dosing of dofetilide on QT interval.Practitioner acceptance of the dofetilide risk-management program.Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.[Pharmacological cardioversion of atrial fibrillation].Unveiling the remodeled atrium: lessons from the early recurrence of atrial fibrillation.Hemodynamic Responses to Tracheal Intubation in Elderly Patients: Intravenous or Spray of Lidocaine versus Fentanyl.
P2860
Q27012532-A3D7B1BB-DFF3-4AAA-B717-F59F48621666Q28182304-088ADCED-1647-4342-92EF-5B684E0E669DQ30669779-8200FD87-5585-4E04-8854-CAC4686BA8C5Q33843408-F3E60558-C6BA-4286-8670-77A9229D36A4Q33854123-B4C4893B-D814-40E0-8F8A-C7C88C4A7E20Q34339685-995F13CC-7380-4B6A-B9CF-3890567AAFB8Q34984908-5057E8BB-F93F-4652-BE92-39E1048ADC31Q35127400-189E1E95-6C49-4DEC-8F20-EDA1CAD5CB24Q35579908-0A7B7C95-CE96-487F-BB13-2CEECE1D626BQ35612755-B04D62F1-7A18-4C3A-AEDD-64188337C19BQ35785780-3127DF20-4A6C-4014-868A-2F7AE57DAAE6Q35892167-3C0BDA9E-F5B0-40F5-9061-7D88AF19C7F9Q37624444-74715A7B-1BC6-4216-B834-4D50F97A6FF3Q37723895-84617B9B-3342-4386-BA72-DF8682A0CD27Q38819882-C7BC25C8-9B91-40BF-B927-D64B9107F202Q41720828-B89BE923-E7DD-44A6-8B1A-1519393DD330Q41720833-02CB4F65-0F41-4FC8-B117-21B6E32CC733Q42018951-D6CAA569-FB7C-450C-BE43-DFE0C3DD956EQ42779952-2032C032-EEE6-418C-9EC3-52824B9E007EQ44098833-81DE79CB-4261-4214-B572-7BBAC49BA4DDQ44360562-D4944636-4A9A-4198-9E40-0A6154133AF6Q45237037-D91EC44F-BE91-4D5D-85AA-2CABB507CA1FQ46734897-C22BE406-BEFD-4873-B5A7-268DE92DC653Q49290904-D7109389-5FCA-43D4-88A4-6A248990D186
P2860
Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Proarrhythmia with class III a ...... rs, and clinical implications.
@en
type
label
Proarrhythmia with class III a ...... rs, and clinical implications.
@en
prefLabel
Proarrhythmia with class III a ...... rs, and clinical implications.
@en
P2860
P1476
Proarrhythmia with class III a ...... rs, and clinical implications.
@en
P2093
Hohnloser SH
P2860
P304
P356
10.1111/J.1540-8167.1995.TB00368.X
P433
P577
1995-10-01T00:00:00Z